Publications by authors named "Matteo Repetto"

Claim this Profile
N
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.
Alison M Schram, Soo-Ryum Yang, Genessa Kahn, Rogelio Velasco, Matteo Repetto

J Natl Cancer Inst· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC.
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, Felix H Gottlieb, Francesco Facchinetti, Matteo Repetto

J Thorac Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic landscape of breast cancer in elderly patients.
Pier Selenica, Higinio Dopeso, Matteo Repetto, Thais Basili, Andrea M Gazzo

NPJ Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.
Christopher J Schwartz, Iskender Genco, Matteo Repetto, Daniel Muldoon, Andrea Gazzo

NPJ Breast Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.
Christopher J Schwartz, Iskender Genco, Matteo Repetto, Daniel Muldoon, Andrea Gazzo

Res Sq· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Yonina R Murciano-Goroff, Valentina Foglizzo, Jason Chang, Natasha Rekhtman, Ann Elizabeth Sisk, Matteo Repetto

Clin Transl Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions.
Antoine Desilets, Matteo Repetto, Soo-Ryum Yang, Alexander Drilon

Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular tumor board in patients with metastatic breast cancer.
Luca Boscolo Bielo, Elena Guerini Rocco, Edoardo Crimini, Matteo Repetto, Mariano Lombardi

Breast Cancer Res Treat· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Oncology: 2024 in Review.
Matteo Repetto, Nicole Fernandez, Alexander Drilon, Debyani Chakravarty

Cancer Discov· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit.
Angela Esposito, Edoardo Crimini, Carmen Criscitiello, Carmen Belli, Roberta Scafetta, Matteo Repetto

Cancers (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.
Antoine Desilets, Matteo Repetto, Alexander Drilon

Clin Transl Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Monica F Chen, Matteo Repetto, Clare Wilhelm, Alexander Drilon

Drugs· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers.
Carmen Belli, Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Raimondo Scalia

Oncologist· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Paola Roa, Valentina Foglizzo, Guilherme Harada, Matteo Repetto, Amanda Kulick

Br J Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones

NPJ Precis Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers.
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones

NPJ Precis Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
Luca Boscolo Bielo, Matteo Repetto, Edoardo Crimini, Carmen Belli, Elisabetta Setola

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.
Luca Boscolo Bielo, Carmen Belli, Edoardo Crimini, Matteo Repetto, Liliana Ascione

Oncologist· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NTRK gene fusion testing and management in lung cancer.
Matteo Repetto, Marina Chiara Garassino, Herbert H Loong, Fernando Lopez-Rios, Tony Mok

Cancer Treat Rev· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.
Edoardo Crimini, Giulia Tini, Paolo Tarantino, Liliana Ascione, Matteo Repetto

Oncologist· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.
Luca Mazzarella, Federica Giugliano, Eleonora Nicolo, Angela Esposito, Edoardo Crimini, Matteo Repetto

Oncologist· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting.
Edoardo Crimini, Luca Boscolo Bielo, Pier Paolo Maria Berton Giachetti, Gloria Pellizzari, Gabriele Antonarelli, Matteo Repetto

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones

bioRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variant allele frequency: a decision-making tool in precision oncology?
Luca Boscolo Bielo, Dario Trapani, Matteo Repetto, Edoardo Crimini, Carmine Valenza

Trends Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of Wild-Type Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib.
Malini M Gandhi, Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa S Gildenberg

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis